AMAG Pharmaceuticals downgraded to "neutral"

07/29/10 - Robert W. Baird

NEW YORK, July 29 (newratings.com) - Analysts at Robert W Baird downgrade AMAG Pharmaceuticals Inc (AMAG) from "outperform" to "neutral." The target price has been reduced from $40 to $36.